Colorectal Oncology Research Review, Issue 47
In this issue:
Survival benefit to adjuvant celecoxib in PIK3CA-mutated colon cancer
High response rates to neoadjuvant immunotherapy in localised dMMR colon cancer
Sotorasib–panitumumab promising for chemo-refractory KRAS G12C-mutated mCRC
Anti-PD-1, HDAC inhibitor and anti- VEGF for MSS/pMMR mCRC
Negative hyperselection using ctDNA may inform front-line use of anti-EGFR
Features of microsatellite instability in pMMR CRC
SCARCE: no benefit to atezolizumab + chemo in anal cancer
Nivolumab + relatlimab beneficial in previously treated MSI-H/dMMR mCRC
Immunoscore prognostic for DFS in stage 3 CRC
Primary tumour resection vs chemotherapy for CRC with unresectable metastases
Expert contributor
Dr Matthew Burge
Dr Matthew Burge, is a medical oncologist and staff specialist at the Royal Brisbane Hospital and a visiting specialist at the Rockhampton Base Hospital. He undertook his undergraduate training in Manchester, UK before moving to Australia in 1996. After obtaining his FRACP in 2004 he moved back to the UK to undertake a clinical fellowship […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.